Back to search

Article

Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine Candidate

2021-08-25

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> SARS-CoV-2 protein subunit vaccines are being evaluated by multiple manufacturers to fill the need for low-cost, easy to scale, safe, and effective COVID-19 vaccines for global access. Vaccine candidates relying on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein have been the focus of our development program. In this paper, we report on the generation of th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f9ac9c0b-0c95-5759-92f1-a82205a82d77
DOI
10.1101/2021.08.24.457518
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateDOI 10.1101/2021.08.24.457518
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceSemantic proximity
Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessSemantic proximity
Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infectionSemantic proximity
Scale-up Production and Immunological Assessment of Recombinant SARS- CoV-2 Spike RBD in Pichia pastorisSemantic proximity
Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopesSemantic proximity
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity
A study protocol to prepare an RBD protein for vaccine against COVID-19Semantic proximity
Computationally designed multi-epitope vaccine construct targeting the SARS-CoV-2 spike protein elicits robust immune responses in silicoSemantic proximity
Designed SARS‐CoV‐2 receptor binding domain variants form stable monomersSemantic proximity
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity
Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse ModelSemantic proximity
Select a neighboring publication to make it the new centre.